LARIMAR THERAPEUTICS INC (LRMR)

Oversold Conditions For Larimar Therapeutics (LRMR)

LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023

LRMR stock results show that Larimar Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Larimar Therapeutics (NASDAQ:LRMR) just reported results for the fourth quarter...

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

Positive top-line data from Phase 2 dose exploration study of nomlabofusp, which was generally well-tolerated, with dose-dependent increases in tissue...

Investors Grab LRMR Even Cheaper Than Its Secondary Stock Offering

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia

Study will inform on long-term safety profile and tissue frataxin levels OLE initiated with 25 mg daily subcutaneous injections of nomlabofusp Frataxin...

Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference

BALA CYNWYD, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company...

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

BALA CYNWYD, Pa., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused...

Larimar Therapeutics rises after pricing $150M stock offering (NASDAQ:LRMR)

Larimar Therapeutics (LRMR) announces a public offering to raise $150M, driving shares up 11% premarket.

Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

BALA CYNWYD, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused...

Larimar Therapeutics announces proposed underwritten public offering (NASDAQ:LRMR)

Larimar Therapeutics announces underwritten public offering of common stock and pre-funded warrants for further development and corporate purposes.

Larimar Therapeutics Announces Proposed Underwritten Public Offering

BALA CYNWYD, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused...

Biogen gets EU approval for Friedrich's ataxia drug (NASDAQ:BIIB)

Biogen (BIIB) said it has received EU approval for its drug Skyclarys for the treatment of Friedreich’s ataxia, or FA, in patients aged 16 years and older. Read more here.

Larimar aiming to file for accelerated approval in 2H 2025 (NASDAQ:LRMR)

Larimar Therapeutics (LRMR) said it is aiming to file for FDA accelerated approval of its drug nolabofusp for the treatment of Friedreich's Ataxia in the 2H 2025. Read more here.

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia

Nomlabofusp was generally well tolerated following repeated subcutaneous injections in patients in the 25 and 50 mg cohorts with no serious adverse...

Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024

These two biotech stocks sport notable 12-month price targets. However, they are also uber-risky.

Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Completed full enrollment and dosing of the 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial; based on blinded observations during...

Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference

BALA CYNWYD, Pa., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused...

Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors

BALA CYNWYD, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused...

Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference

BALA CYNWYD, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused...

Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Initiation cleared for 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial following FDA review of unblinded 25 mg cohort Phase 2...

Larimar, Design higher as they benefit from Biogen deal for Reata

Larimar Therapeutics, which has a candidate in phase 2 for Friedreichs Ataxia, is up 22% Friday, a beneficiary of Biogen's acquisition of Reata. Read more here.